All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @jewell_samone on TikTok · 36s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @jewell_samone's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Hi all this is what I ate today is a fat girl on a weight loss journey supported by osmec.
  2. 0:03I started my day with the protein coffee it was a caramel premiere protein shake with some cold brew.
  3. 0:07Chicken, sweet potato, and mac and cheese for lunch. I started eating before I filmed so there
  4. 0:11was like a few more pieces that were not shown but this is what my plate looked like when I was done.
  5. 0:15Later on the day I snacked on a cinnamon toast crunch cereal bowl these have been
  6. 0:18taught to me at work for weeks and I finally just allowed myself to have a treat. I grabbed three
  7. 0:22cuties but only ended up being hungry enough for one. Since I am a real person I had half a bag of
  8. 0:26ruffles in bed when I got home. I was out of town this weekend so I have no groceries in the house
  9. 0:30so I decided to go to Chick-fil-A for dinner. Tonight's lineup was a bowl of chicken noodle soup and a
  10. 0:34kale crunch salad. Bye!

@jewell_samone's GLP-1 weight loss content, fact-checked

JEWELL SAMONE 🎀🍸🪩✨🩷

TikTok creator

805.2K viewsWatch on TikTok

Quick answer

The creator documents a typical eating day while using semaglutide (Ozempic) off-label for weight loss, a common real-world practice documented in peer-reviewed literature despite Wegovy carrying the formal FDA approval for chronic weight management. Her described intake pattern, protein-anchored meals, moderate carbohydrates, and occasional snacks, is consistent with the flexible dietary approach used in major semaglutide efficacy trials like STEP 1 (Wilding et al., 2021). No unsafe behaviors, supplement combinations, or dosing claims appear in the video.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @jewell_samone's GLP-1 weight loss content, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

@jewell_samone's GLP-1 weight loss content, fact-checked should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@jewell_samone's GLP-1 weight loss content, fact-checked" from JEWELL SAMONE 🎀🍸🪩✨🩷. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator documents a typical eating day while using semaglutide (Ozempic) off-label for weight loss, a common real-world practice documented in peer-reviewed literature despite Wegovy carrying the formal FDA approval for chronic weight management.

The reason this review is not generic is the source wording and the canonical claim label "glp1 eat food with me what i ate today plus size weight loss." In this clip, the useful excerpt is: "Hi all this is what I ate today is a fat girl on a weight loss journey supported by osmec." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Ozempic is FDA-approved for type 2 diabetes; Wegovy is the approved semaglutide formulation for chronic weight management.
People who land here are usually trying to understand whether the GLP-1 social video fact-checks claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator documents a typical eating day while using semaglutide (Ozempic) off-label for weight loss, a common real-world practice documented in peer-reviewed literature despite Wegovy carrying the formal FDA approval for chronic weight management.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator documents a typical eating day while using semaglutide (Ozempic) off-label for weight loss, a common real-world practice documented in peer-reviewed literature despite Wegovy carrying the formal FDA approval for chronic weight management. Her described intake pattern, protein-anchored meals, moderate carbohydrates, and occasional snacks, is consistent with the flexible dietary approach used in major semaglutide efficacy trials like STEP 1 (Wilding et al., 2021). No unsafe behaviors, supplement combinations, or dosing claims appear in the video.
  • Semaglutide at 2.4mg produced an average 14.9% body weight reduction in 68 weeks without requiring a specific diet plan (Wilding et al., 2021, NEJM).
  • Ozempic is FDA-approved for type 2 diabetes; Wegovy is the approved semaglutide formulation for chronic weight management. Off-label prescribing is common but patients deserve to know the difference.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Semaglutide at 2.4mg produced an average 14.9% body weight reduction in 68 weeks without requiring a specific diet plan (Wilding et al., 2021, NEJM).
  • Ozempic is FDA-approved for type 2 diabetes; Wegovy is the approved semaglutide formulation for chronic weight management. Off-label prescribing is common but patients deserve to know the difference.
  • GLP-1 medications reduce appetite by slowing gastric emptying and acting on hypothalamic satiety centers, which explains spontaneous portion reduction like eating one clementine instead of three.
  • Roughly two-thirds of weight lost on semaglutide is regained within one year of stopping the medication, per STEP 4 (Rubino et al., 2021, JAMA).
  • Protein intake during GLP-1-assisted weight loss supports lean muscle preservation; a protein-forward breakfast like the creator describes aligns with guidance in Lean et al. (2023, Obesity Reviews).
  • No single food diary, including this one, should be treated as a clinical template. Individual responses to GLP-1 therapy vary based on dose, duration, metabolic history, and other factors.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @jewell_samone actually say?

@jewell_samone shared a straightforward food diary, describing herself as a "fat girl on a weight loss journey supported by Ozempic." She ate protein coffee, chicken with sweet potato and mac and cheese, cereal, citrus, chips in bed, and Chick-fil-A for dinner. No dramatic claims, no supplement pitches. Just honest documentation of a real eating day, including the "half a bag of ruffles in bed" moment most people skip when filming.

This is a behavioral transparency video, not a medical tutorial. She is not prescribing dosing, not claiming Ozempic cures anything, and not telling viewers to eat the way she eats. The implicit message is: this is what eating on GLP-1 medication actually looks like for a real person. That framing matters for how we evaluate it.

Does the science back this up?

The honest answer is: mostly yes, with some important nuance. GLP-1 receptor agonists like semaglutide (the active ingredient in Ozempic and Wegovy) reduce appetite through multiple pathways, including slowing gastric emptying and acting on hypothalamic satiety centers. The result is that most people eat less without rigid restriction.

A 2021 trial by Wilding et al. in the New England Journal of Medicine found that participants on 2.4mg semaglutide lost an average of 14.9% of body weight over 68 weeks, without being required to follow a specific diet plan. The key mechanism is appetite suppression, not food elimination. Eating a mix of protein, carbohydrates, and yes, some chips, is entirely consistent with how GLP-1 trials are actually conducted. Participants in those trials were given general lifestyle counseling, not strict meal plans. The video inadvertently illustrates something the research supports: reduced total intake matters more than food category policing.

What did they get wrong (or right)?

She largely got it right, which is not the answer people expect from a fact-check. There is no pseudoscience here. She did not claim Ozempic is a miracle drug, did not suggest viewers start it without a doctor, and did not overstate her results.

One thing worth flagging: she says she is "on Ozempic" for weight loss, but Ozempic is FDA-approved for type 2 diabetes management. Wegovy, the same compound at a higher approved dose, carries the FDA approval for chronic weight management. This is a common real-world confusion, and it is not her fault, but it is clinically relevant. Patients are frequently prescribed Ozempic off-label for weight loss because Wegovy faces supply constraints. A 2023 analysis in JAMA Internal Medicine by Shao et al. documented widespread off-label semaglutide prescribing for obesity. She is likely describing a real and common clinical scenario, but the distinction between brand names and approved indications is worth knowing.

The protein coffee as a morning anchor is actually a reasonable behavioral pattern. Adequate protein intake supports lean mass preservation during GLP-1-assisted weight loss, per Lean et al. (2023, Obesity Reviews).

What should you actually know?

GLP-1 medications reduce appetite significantly for most users, but they do not eliminate the need to think about food quality over time. The research supporting semaglutide for weight loss is among the strongest in obesity medicine in decades, but weight regain after stopping medication is well-documented. The STEP 4 trial (Rubino et al., 2021, JAMA) showed participants who discontinued semaglutide regained two-thirds of their lost weight within a year.

What this video models, intentionally or not, is a low-restriction, appetite-guided eating pattern. That is actually what most GLP-1 clinical guidelines recommend: eat when hungry, stop when full, prioritize protein where possible. The chips in bed are not a failure. They are a normal human evening, and the research does not suggest occasional indulgences derail GLP-1 outcomes in the way diet culture implies.

If you are considering GLP-1 therapy, the most important thing is working with a licensed provider who can evaluate your health history, not replicating someone else's food diary on TikTok, however relatable it may be.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

JEWELL SAMONE 🎀🍸🪩✨🩷 · TikTok creator

805.2K views on this video

eat food with me! what i ate today plus size weight loss fat girl fitness glp-1

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about semaglutide at 2.4mg produced an average 14.9% body weight reduction?

Semaglutide at 2.4mg produced an average 14.9% body weight reduction in 68 weeks without requiring a specific diet plan (Wilding et al., 2021, NEJM).

What does the video say about ozempic?

Ozempic is FDA-approved for type 2 diabetes; Wegovy is the approved semaglutide formulation for chronic weight management. Off-label prescribing is common but patients deserve to know the difference.

What does the video say about glp-1 medications reduce appetite by slowing gastric emptying?

GLP-1 medications reduce appetite by slowing gastric emptying and acting on hypothalamic satiety centers, which explains spontaneous portion reduction like eating one clementine instead of three.

What does the video say about roughly two-thirds of weight lost on semaglutide?

Roughly two-thirds of weight lost on semaglutide is regained within one year of stopping the medication, per STEP 4 (Rubino et al., 2021, JAMA).

What does the video say about protein intake during glp-1-assisted weight loss supports lean muscle preservation;?

Protein intake during GLP-1-assisted weight loss supports lean muscle preservation; a protein-forward breakfast like the creator describes aligns with guidance in Lean et al. (2023, Obesity Reviews).

What does the video say about no single food diary, including this one, should be treated?

No single food diary, including this one, should be treated as a clinical template. Individual responses to GLP-1 therapy vary based on dose, duration, metabolic history, and other factors.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by JEWELL SAMONE 🎀🍸🪩✨🩷, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.